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Abstract
XMRV (xenotropic murine leukaemia virus-related virus) is a gammaretrovirus that has been detected in human
patients with prostate carcinoma, chronic fatigue syndrome (CFS) and also in a small percentage of clinically
healthy individuals. It is not yet clear whether the distribution of this virus is primarily limited to the USA or
whether it is causally associated with human disease. If future investigations confirm a broad distribution of XMRV
and its association with disease, this would have an impact on xenotransplantation of porcine tissues and organs.
Xenotransplantation is currently being developed to compensate for the increasing shortage of human material for
the treatment of tissue and organ failure but could result in the transmission of porcine pathogens. Maintenance
of pathogen-free donor animals will dramatically reduce this risk, but some of the porcine endogenous retroviruses
(PERVs) found in the genome of all pigs, can produce infectious virus and infect cultured human cells. PERVs are
closely related to XMRV so it is critical to develop tests that discriminate between them. Since recombination can
occur between viruses, and recombinants can exhibit synergism, recipients should be tested for XMRV before
xenotransplantation.
Questions concerning XMRV detection
XMRV was first detected in prostate carcinomas of
patients who were homozygous for a mutation in the
gene for the antiviral enzyme, ribonuclease L (RNase L)
[1]. Men with two copies of the homozygous mutation
R462Q (QQ) were found to have twice the risk of pros-
tate cancer as males with the non-mutated allele. Inte-
grated XMRV was detected in 8 of 20 of these patients
(40%) using a DNA microarray and RT-PCR analysis. In
heterozygous patients and patients without the muta-
tion, XMRV was found only in 1.5% of prostate
tumours. The sequence of the virus is closely related
(more than 93% DNA sequence identity) to other xeno-
tropic murine retroviruses. Xenotropic viruses infect
only cells from other species. Interestingly, low levels of
XMRV protein expression were detected in a small
number of stromal cells, but not in the tumour cells
themselves. In vitro tests have revealed that the virus
productively infects human cells and that its replication
is susceptible to IFN-b treatment [2]. Another study
identified XMRV proviral DNA in 6% of the prostate
tumours analysed by real time PCR and viral protein
was detected in 23% of 334 prostate tumours using anti-
sera against a panel of murine retroviruses including
XMRV [3]. In that study, infection was associated with
high-grade tumours, but did not correlate with the
RNase L QQ variant. In contrast to previous reports [1],
XMRV proteins were found to be expressed primarily in
tumour cells [3]. Unfortunately screening for XMRV
specific antibodies was not performed, although it is
generally agreed that detection of antibodies is a com-
mon and reliable diagnostic method to detect low level
infections with retroviruses including HIV-1. In cases of
low proviral load, antibody detection can indicate infec-
tion in the absence of positive PCR results [4].
In Europe, XMRV appears to be less common than in
the USA. No XMRV was found in 139 Irish prostate
cancer patients with the RNase L mutation [5]. In a
German study, XMRV-specific sequences were detected
in only in 1 of 105 tissue samples from non-familial
prostate cancer and in 1 of 70 tissue samples from men
without prostate cancer [6]. The two positive samples
Correspondence: DennerJ@rki.de
Retrovirus induced immunosuppression, Robert Koch Institute, Nordufer 20,
D-13353 Berlin, Germany
Denner Retrovirology 2010, 7:16
http://www.retrovirology.com/content/7/1/16
© 2010 Denner; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.were not correlated with homozygosity for the R462Q
mutation. In a larger study, Hohn et al. [6] failed to find
any XMRV-specific sequences in the DNA and RNA
from tumours of 589 German prostate cancer patients,
even though 12.9% of them were shown to be of the
QQ genotype [7]. Most importantly, we did not find
antibodies when sera from 146 patients from this cohort
were tested [7].
A recent study in the USA identified XMRV-specific
proviral DNA in PBMCs from patients suffering from
chronic fatigue syndrome (CFS) [8]. CSF is characterized
by debilitating fatigue, chronic inflammation and other
abnormalities of the immune system such as a defi-
ciency in natural killer cell activity. In 68 of 101 CFS
patients (67%), but also in 8 of 218 (3.7%) healthy con-
trols, XMRV could be detected by PCR [8]. This 3.7%
incidence in healthy controls suggests that several mil-
lion Americans may be infected. Laboratory tests
revealed that virus from patient-derived sera could infect
cultured human cells. The authors detected antiviral
antibodies in 9 out of 18 patients using a test based on
an envelope protein from spleen focus forming virus
which is closely related to XMRV. In contrast, two other
studies found no XMRV in clinically well-characterized
European CFS patients [9,10]. In one of these studies,
PCR analysis revealed no XMRV DNA in 299 samples,
although some serum samples showed XMRV neutralis-
ing activity. Only one of these was from a CFS patient
[9]. In the other study, neither XMRV nor murine leu-
kemia virus sequences were detected. The authors came
to the conclusion the XMRV is not a contributory factor
in the pathogenesis of CSF [10].
In light of these results, the finding of XMRV in pros-
tate tumours and CFS patients in the USA has to be
treated with great caution. In the past, numerous retro-
viruses have been reported in human tissues and cul-
tured cells (for review see [11]). Some of these have
later been shown to be contaminating animal viruses
w i t hu n k n o w no r i g i na n df u n c t i o n .O n l yH I V - 1a n d
HIV-2, both of which induce acquired immunodefi-
ciency syndromes (AIDS), and the human T-lymphotro-
pic viruses, HTLV-1 and HTLV-2, which induce adult
T-cell leukaemia and HTLV-associated myelopathy/tro-
pical spastic paraperesis, have been proven to be linked
to human diseases. Highly sensitive methods such as
PCR allow detection of minimal traces of retroviruses
but also detect sample contamination. Indeed, contami-
nating retroviruses, mainly gammaretroviruses, have
been found in numerous human cell lines (for literature
see the latest report concerning this topic, [12]).
Trans-species transmission of retroviruses has
occurred frequently during evolution (for review see
[13]), and HIV-1 is the best-known example. Trans-spe-
cies transmission has also been reported for
gammaretroviruses closely related to XMRV, for exam-
ple the Koala retrovirus [14]. Important questions
remain to be answered: How and when did this murine
xenotropic virus infect humans? Is it a direct infection
from rodents to susceptible humans or is the virus
spreading through human populations resulting in high
virus load in (immunosuppressed) tumours and CFS
patients? Is a third species transmitting the virus from
mice to humans? As mentioned above, 3.7% of healthy
controls from one study in the USA were virus positive
[3]. Why is the virus common in the USA but rare in
Europe? Are there specific populations of rodents in the
USA releasing this virus? Why is disease associated with
XMRV in the USA but not in Europe? Is XMRV a pas-
senger virus replicating in immuno-compromised indivi-
duals or does this virus contribute directly to disease
progression? The immunosuppressive properties charac-
teristic of all retroviruses [15] could contribute to
tumour progression as well as to the symptoms of CSF.
If XMRV is indeed widely distributed in the human
population and associated with tumours and CSF,
should blood donors be tested in order to avoid XMRV
transmission?
PERVs, XMRV and possible implications for
xenotransplantation
With so many unanswered questions, much work
remains to be done. At this early point in XMRV
research, areas should be identified in which this virus
may cause a serious impact on human health. One of
these areas may be the xenotransplantation of porcine
tissues and organs to humans. Xenotransplantation is a
potential solution for the shortage of allogeneic human
organs. Designated pathogen-free breeding and mainte-
nance of pigs can prevent the transmission of most por-
cine pathogens; however, porcine endogenous
retroviruses (PERVs) are integrated in the pig genome
and can be released from normal pigs and infect human
cells in vitro [16,17]. In the past, highly sensitive meth-
ods had been developed to detect PERV infection.
A PCR study of more than 200 patients treated with pig
material for PERV transmission found no viral DNA
[18]. However, three of the patients showed a clear anti-
body response against the p27Gag of PERV in a Wes-
tern blot assay, and a small percentage of blood donors
(5%) have also been found to react with the p27Gag of
PERV [18,19]. Since antibodies against the Env protein
of PERV were not found, this reaction was classified as
not specific for PERV following the rules applied for
HIV-1 diagnostic tests. Is it possible that the antibody
response detected was against a related retrovirus such
as XMRV?
If XMRV is indeed circulating in the human population,
it has important implications for xenotransplantation.
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and XMRV, and the potential for recombination between
the two viruses should be investigated. Recombination
between the human tropic PERV-A and the ecotropic
PERV-C has been described in normal pigs and in mela-
noma-bearing animals, and recombinant PERV-A/C was
characterized by high replication titers [20-22]. Whether
XMRV and PERV recombine remains unclear, however
co-packaging [23] and pseudotyping [24] between PERV
and murine retroviruses have been described. Although
the sequence identity between PERV and XMRV is only
approximately 53%, there are regions with higher homol-
ogy that would allow recombination.
This raises new questions: Should the xenotransplant
recipients be pre-screened for XMRV to avoid recombi-
nation? What measures can be taken when XMRV
infection is detected in such a screen? Before dealing
with these specific details, it is necessary to address the
important broad questions concerning the distribution
of XMRV and its impact on human health.
Added in proof
In a recent case-control study van Kuppeveld et al. [25]
detected no XMRV sequences in any of the Dutch
patients with CFS or controls.
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